MarketPulse

Mounjaro

7 articles
BenzingaBenzinga··Vandana Singh

Eli Lilly Surges on China Expansion Despite Supreme Court Lawsuit Setback

Eli Lilly announces $3B China investment and Mounjaro reimbursement win, but faces multibillion-dollar lawsuit over Actos disclosures.
LLYAAPLTAKclass action lawsuitMounjaro
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Eli Lilly's GLP-1 Dominance Faces Reality Check as Valuation Reaches Peak Levels

Eli Lilly's GLP-1 drugs drive 56% of revenues with explosive growth, but 43x P/E valuation leaves no room for disappointment amid intensifying competition and future patent risks.
PFELLYNVOGLP-1 drugsweight loss drugs
Investing.comInvesting.com··Jeffrey Neal Johnson

Eli Lilly's $3B China Bet: Securing GLP-1 Dominance in World's Largest Metabolic Market

Eli Lilly commits $3 billion to decade-long China expansion, targeting 141 million diabetics and 600 million overweight adults amid intense domestic competition.
LLYNVOsupply chainGLP-1 drugs
BenzingaBenzinga··Vandana Singh

Eli Lilly Warns of Unknown Impurity in Compounded Weight Loss Drugs

Eli Lilly warns of unidentified impurity in compounded tirzepatide weight loss drugs mixed with vitamin B12, urging FDA recalls and stricter oversight.
LLYweight loss drugsZepbound
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Lilly's Valuation Trap vs. Merck's Dividend Appeal: A Tale of Two Pharma Giants

Eli Lilly trades at expensive P/E of 44 with meager 0.6% dividend yield despite GLP-1 success. Merck offers better value at P/E 16 and 2.8% yield with 30+ year dividend track record.
MRKLLYvaluationdividend stocks
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Eli Lilly's GLP-1 Dominance Masks Valuation Risks; Analysts Eye Cheaper Alternatives

Eli Lilly trades at premium 44 P/E despite GLP-1 concentration risks. Novo Nordisk and Pfizer offer higher yields and lower valuations.
PFELLYNVOvaluationbiotech
The Motley FoolThe Motley Fool··Adria Cimino

Eli Lilly Expands Obesity Drug Lead With Clinical Win and Product Innovation

Eli Lilly strengthens obesity drug dominance as competitor's treatment fails trials and Lilly launches new monthly-dose Zepbound pen, commanding 60% market share.
PFELLYNVOVKTXclinical trialsGLP-1 drugs